Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 5/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 3/20 | 0.34 |
| ▸ | ACACA | Q13085 | 3/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976749 | 0.92 | PDK2 (0.35) | PDK2ACACA | |
| SCHEMBL9976732 | 0.90 | COMT (0.39) | GLO1CKS1BSKP2PDK2PIK3CD | |
| SCHEMBL9976764 | 0.88 | PDK2 (0.36) | TOP1GLO1CKS1BSKP2PDK2 | |
| SCHEMBL9976741 | 0.87 | PDK2 (0.35) | TOP1PDK2ACACA | |
| SCHEMBL9976762 | 0.86 | COMT (0.39) | TOP1GLO1CKS1BSKP2PDK2 | |
| SCHEMBL13642970 | 0.82 | BACE1 (0.38) | TOP1DHODH | |
| SCHEMBL9980024 | 0.81 | PDK2 (0.42) | PDK2 | |
| SCHEMBL13083898 | 0.81 | PDK2 (0.44) | TOP1PDK2DHODHACACA | |
| SCHEMBL9976739 | 0.81 | PDK2 (0.35) | PDK2FEN1 | |
| SCHEMBL20250390 | 0.80 | ACACA (0.36) | PDK2ACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877354-B2 | Heterocyclic compound and organic light-emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8877354-B2 | Heterocyclic compound and organic light-emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-21 | — | — | US | disclosed |
| WO-2011024391-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | ORC3, CYP1A1, CRY1 | TOP1 1962/4885GLO1 993/4885CKS1B 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.